Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

375 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The consistency of the treatment effect of an ACE-inhibitor based treatment regimen in patients with vascular disease or high risk of vascular disease: a combined analysis of individual data of ADVANCE, EUROPA, and PROGRESS trials.
Brugts JJ, Ninomiya T, Boersma E, Remme WJ, Bertrand M, Ferrari R, Fox K, MacMahon S, Chalmers J, Simoons ML. Brugts JJ, et al. Among authors: macmahon s. Eur Heart J. 2009 Jun;30(11):1385-94. doi: 10.1093/eurheartj/ehp103. Epub 2009 Apr 4. Eur Heart J. 2009. PMID: 19346520 Free article.
Genetic determinants of treatment benefit of the angiotensin-converting enzyme-inhibitor perindopril in patients with stable coronary artery disease.
Brugts JJ, Isaacs A, Boersma E, van Duijn CM, Uitterlinden AG, Remme W, Bertrand M, Ninomiya T, Ceconi C, Chalmers J, MacMahon S, Fox K, Ferrari R, Witteman JC, Danser AH, Simoons ML, de Maat MP. Brugts JJ, et al. Among authors: macmahon s. Eur Heart J. 2010 Aug;31(15):1854-64. doi: 10.1093/eurheartj/ehq169. Epub 2010 Jun 10. Eur Heart J. 2010. PMID: 20538738 Clinical Trial.
A pharmacogenetic analysis of determinants of hypertension and blood pressure response to angiotensin-converting enzyme inhibitor therapy in patients with vascular disease and healthy individuals.
Brugts JJ, Isaacs A, de Maat MP, Boersma E, van Duijn CM, Akkerhuis KM, Uitterlinden AG, Witteman JC, Cambien F, Ceconi C, Remme W, Bertrand M, Ninomiya T, Harrap S, Chalmers J, Macmahon S, Fox K, Ferrari R, Simoons ML, Danser AJ. Brugts JJ, et al. Among authors: macmahon s. J Hypertens. 2011 Mar;29(3):509-19. doi: 10.1097/HJH.0b013e328341d117. J Hypertens. 2011. PMID: 21157371
Monitoring initial response to Angiotensin-converting enzyme inhibitor-based regimens: an individual patient data meta-analysis from randomized, placebo-controlled trials.
Bell KJ, Hayen A, Macaskill P, Craig JC, Neal BC, Fox KM, Remme WJ, Asselbergs FW, van Gilst WH, Macmahon S, Remuzzi G, Ruggenenti P, Teo KK, Irwig L. Bell KJ, et al. Among authors: macmahon s. Hypertension. 2010 Sep;56(3):533-9. doi: 10.1161/HYPERTENSIONAHA.110.152421. Epub 2010 Jul 12. Hypertension. 2010. PMID: 20625081
Age-stratified and blood-pressure-stratified effects of blood-pressure-lowering pharmacotherapy for the prevention of cardiovascular disease and death: an individual participant-level data meta-analysis.
Blood Pressure Lowering Treatment Trialists' Collaboration. Blood Pressure Lowering Treatment Trialists' Collaboration. Lancet. 2021 Sep 18;398(10305):1053-1064. doi: 10.1016/S0140-6736(21)01921-8. Epub 2021 Aug 27. Lancet. 2021. PMID: 34461040 Free PMC article.
Combined effects of routine blood pressure lowering and intensive glucose control on macrovascular and microvascular outcomes in patients with type 2 diabetes: New results from the ADVANCE trial.
Zoungas S, de Galan BE, Ninomiya T, Grobbee D, Hamet P, Heller S, MacMahon S, Marre M, Neal B, Patel A, Woodward M, Chalmers J; ADVANCE Collaborative Group; Cass A, Glasziou P, Harrap S, Lisheng L, Mancia G, Pillai A, Poulter N, Perkovic V, Travert F. Zoungas S, et al. Among authors: macmahon s. Diabetes Care. 2009 Nov;32(11):2068-74. doi: 10.2337/dc09-0959. Epub 2009 Aug 3. Diabetes Care. 2009. PMID: 19651921 Free PMC article. Clinical Trial.
Perindopril-based blood pressure lowering in individuals with cerebrovascular disease: consistency of benefits by age, sex and region.
Rodgers A, Chapman N, Woodward M, Liu LS, Colman S, Lee A, Chalmers J, MacMahon S; Perindopril Protection against Recurrent Stroke Study Collaborative Group. Rodgers A, et al. Among authors: macmahon s. J Hypertens. 2004 Mar;22(3):653-9. doi: 10.1097/00004872-200403000-00030. J Hypertens. 2004. PMID: 15076173 Clinical Trial.
375 results